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Abstract
Background
Soluble tumor necrosis factor receptors 1 (sTNFR1) and 2 (sTNFR2) have been associated
to progression of renal failure, end stage renal disease and mortality in early stages of
chronic kidney disease (CKD), mostly in the context of diabetic nephropathy. The predictive
value of these markers in advanced stages of CKD irrespective of the specific causes of kid-
ney disease has not yet been defined. In this study, the relationship between sTNFR1 and
sTNFR2 and the risk for adverse cardiovascular events (CVE) and all-cause mortality was
investigated in a population with CKD stage 4-5, not yet on dialysis, to minimize the con-
founding by renal function.
Patients andmethods
In 131 patients, CKD stage 4-5, sTNFR1, sTNFR2 were analysed for their association to a
composite endpoint of all-cause mortality or first non-fatal CVE by univariate and multivari-
ate Cox proportional hazards models. In the multivariate models, age, gender, CRP, eGFR
and significant comorbidities were included as covariates.
Results
During a median follow-up of 33 months, 40 events (30.5%) occurred of which 29 deaths
(22.1%) and 11 (8.4%) first non-fatal CVE. In univariate analysis, the hazard ratios (HR) of
sTNFR1 and sTNFR2 for negative outcome were 1.49 (95% confidence interval (CI): 1.28-
1.75) and 1.13 (95% CI: 1.06-1.20) respectively. After adjustment for clinical covariables
(age, CRP, diabetes and a history of cardiovascular disease) both sTNFRs remained inde-
pendently associated to outcomes (HR: sTNFR1: 1.51, 95% CI: 1.30-1.77; sTNFR2: 1.13,
95% CI: 1.06-1.20). A subanalysis of the non-diabetic patients in the study population con-
firmed these findings, especially for sTNFR1.
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Conclusion
sTNFR1 and sTNFR2 are independently associated to all-cause mortality or an increased
risk for cardiovascular events in advanced CKD irrespective of the cause of kidney disease.
Introduction
Chronic kidney disease (CKD) has been linked to increased risk for cardiovascular disease and
mortality independent of traditional cardiovascular risk factors [1]. This has at least in part
been attributed to micro-inflammation, since inflammatory markers were associated to cardio-
vascular disease or mortality in different CKD cohorts not on dialysis [2–5] as well as on dialy-
sis [6–8].
Soluble tumor necrosis factor receptor 1 (sTNFR1) and soluble tumor necrosis factor recep-
tor 2 (sTNFR2) are the circulating forms of their membrane bound counterparts (mTNFR1
and mTNFR2) which are essential for tumor necrosis factor alpha (TNFα)-signalling via differ-
ent pathways. Interaction between TNFα and both mTNFR leads to a pro-inflammatory stimu-
lus via activation of nuclear factor kappa B (NF-κB) or activator protein 1 (AP-1), while only
mTNFR1 contains a death domain through which signalling leads to apoptosis [9]. The soluble
receptors are released into circulation via shedding of membrane receptors, in exosomes or via
alternative splicing of mRNA transcripts which leads to a loss of the transmembrane and cyto-
plasmic domains [10].
In contrast to TNFα, which failed to be associated to mortality or cardiovascular events in
CKD [2], both circulating receptors are potential biomarkers in chronic kidney disease as pre-
dictors for outcome, be it in selected populations with diabetic nephropathy [11–13] or in early
or moderate CKD [12,14]. Whereas diabetes can be seen as a pro-inflammatory stimulus per se
and a broad range of GFR implies a higher risk for confounding because of the known relation-
ship of sTNFRs with kidney function, the association of both sTNFRs to mortality and cardio-
vascular events has not yet been evaluated in a CKD population that was not selected on a
specific cause nor in patients who suffer from advanced stages of disease.
In the present study, we evaluated the predictive value of sTNFR1 and sTNFR2 for the risk
for all-cause mortality or cardiovascular events in a population with advanced CKD (stage 4–5
not on dialysis). Evaluating outcome in advanced CKDminimizes the influence of eGFR on
outcomes and on the concentration of the evaluated marker. This may allow to generate hy-
potheses on the contribution of other important mechanisms in the pathophysiology of CKD,
such as inflammation, while reducing the impact of their intrinsic association to
kidney function.
Patients and Methods
Ethics statement
This study was approved by the local Ethics Committee (Ethical Committee, Ghent University
Hospital, Ghent, Belgium) and performed in accordance to the Declaration of Helsinki. Writ-
ten informed consent was obtained from all participants.
Study population
All non-transplanted CKD patients stage 4 and 5 not on dialysis, attending the Nephrology
outpatient clinic and included in the biobank sample collection of the Nephrology Department
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of the Ghent University Hospital between January 2011 and August 2012, were included in this
study (n = 131). Samples were processed immediately after collection and stored at—80°C.
Outcomes were registered prospectively.
Baseline clinical parameters (age, gender, blood pressure, heart rate, height and weight) and
etiology of the underlying kidney disease (vascular, diabetic nephropathy, glomerular disease/
auto-immune, interstitial/postrenal, others and unknown) were registered. Body mass index
(BMI) was calculated as weight/height2 (kg/m2), mean arterial pressure (MAP) as the sum of 1/
3 of the systolic and 2/3 of the diastolic blood pressure and pulse pressure (PP) as the difference
between systolic and diastolic blood pressure. Estimated glomerular filtration rate (eGFR) was
calculated based on the creatinine-based CKD-EPI formula [15]. The following comorbidities
were recorded: cardiovascular history when at least one of the following was present: arterial
cardiovascular disease (coronary, cerebral or peripheral), atrial fibrillation or heart failure (re-
quiring hospitalisation); malignancy; diabetes mellitus, defined as a history of diabetes or treat-
ment with insulin or oral antidiabetic drugs; hypertension, defined as current hypertension
(>140/90 mmHg) or the use of antihypertensive drugs; hypercholesterolemia, defined as histo-
ry of elevated serum cholesterol or treatment with lipid lowering drugs and smoking status (ac-
tive versus no/former smoker). The start of renal replacement therapy (RRT) during follow-up
was registered.
Patients were followed and adverse cardiovascular events (CVE), defined as acute coronary
syndrome (ACS), coronary artery bypass graft (CABG), percutaneous transluminal coronary
angioplasty (PTCA) and stroke, and all-cause mortality were registered until September 19th
2014. The composite endpoint in this study was all-cause mortality or a first non-fatal CVE,
whichever occurred first. The collection of the events was done by a single researcher and was
based on investigation of the hospital patient file.
Measurements
The concentrations of sTNFR1, sTNFR2 and TNFα, were determined on plasma samples by
ELISA (R&D Systems, Abingdon, United Kingdom). Serum creatinine, C-reactive protein
(CRP) and albuminemia were measured with routine laboratory methods.
Statistical analysis
Continuous data are expressed as mean with standard deviation or median with interquartile
range depending on their distribution, and analysed by Student’s t-test or MannWhitney-test
as appropriate. Binary categorical data are expressed as frequencies and analysed with chi-
square test. Linear regression analysis was performed between sTNFR1 and sTNFR2 as depen-
dent variables and the different clinical parameters as independent variables.
Univariate and multivariate analyses were performed by using Cox proportional hazards
models to estimate the relationship between sTNFR1 and sTNFR2, as continuous variables and
the risk for negative outcome defined as the composite endpoint of all-cause mortality or the
occurrence of a first non-fatal CVE. Univariate analysis was also performed to assess the associ-
ation between the baseline clinical variables and outcome.
In multivariate analysis, separate models were built for sTNFR1 and sTNFR2. Due to collin-
earity, sTNFR1 and sTNFR2 were not entered together in a model. First, age and gender were
forced into a model with sTNFR1 or sTNFR2 (model 1). In the second model, possible con-
founders, which correlated significantly with sTNFR1 or sTNFR2, i.e. eGFR, CRP and TNFα
(the latter only for sTNFR2), were added to model 1. The third model included the clinical cov-
ariables which reached a significance of p< 0.05 with outcome in univariate analysis (age,
CRP, history of cardiovascular disease and diabetes mellitus). In a separate analysis in the
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group of patients for which albumin concentrations were available (n = 73), albumin was also
included as covariate in the model. Model 2 and 3 were analysed by forward and backward re-
gression procedures based on the likelihood ratio test and gave similar results. In this publica-
tion, only the results of the stepwise forward procedure are reported as hazard ratio (HR) with
a 95% confidence interval (CI).
The analysis described above was repeated in a subgroup analysis of patients with and
without diabetes.
A p-value<0.05 was considered as statistically significant.
All statistical analyses were performed with SPSS Statistics V22.0 (SPSS Inc., Chicago, IL,
USA) for Windows (Microsoft Corp, Redmond, WA, USA).
Results
Baseline clinical characteristics
In this study population including 131 patients with CKD stage 4–5 not on dialysis, the etiology
of the underlying kidney disease was distributed as follows: renal vascular disease, mainly
nephrangiosclerosis, n = 37 (28.2%); diabetic nephropathy, n = 28 (21.4%); glomerular/auto-
immune disease, n = 20 (15.3%); interstitial/postrenal, n = 15 (11.5%); other, mainly autosomal
dominant polycystic kidney disease, (unilateral) nephrectomy or use of calcineurin inhibitors
in liver or heart transplants, n = 23 (17.5%); and unknown n = 8 (6.1%). Forty events (30.5%),
defined as the composite endpoint of all-cause mortality or first non-fatal CVE, occurred after
a total median follow-up of 33 months [interquartile range 24–39 months]. Twenty-nine pa-
tients (22.1%) died (cardiovascular (n = 3), malignancy (n = 3), infection (n = 7), ESRD
(n = 1), unknown (n = 15)) and 11 (8.4%) had a first non-fatal CVE (ACS (n = 1), PTCA
(n = 4), CABG (n = 2), stroke (n = 4)), of which 5 patients died subsequently during follow-up.
Seven events occurred after the start of RRT, which was initiated in 35 patients during follow-
up. Baseline clinical characteristics and biochemical parameters of the entire population and
those with and without event are presented in Table 1. Patients who reached the composite
endpoint, were older, had a higher CRP, lower albumin and had more often a history of cardio-
vascular disease or diabetes. There was no difference in eGFR between both groups, complying
with one of the aims of this study, i.e. to restrict the influence of kidney function on outcome
among subgroups by selecting a patient population with an eGFR over a narrow range. Both
sTNFRs were significantly higher in the group who had an event.
sTNFR1 and sTNFR2 were strongly correlated (r = 0.76, p< 0.001) (Fig. 1). Linear regres-
sion analysis with sTNFR1 and sTNFR2 as dependent variables showed only a correlation with
eGFR (sTNFR1: r = -0.64, p<0.001; sTNFR2: r = -0.50, p< 0.001), CRP (sTNFR1: r = 0.52,
p< 0.001; sTNFR2: r = 0.54, p< 0.001) and albumin (sTNFR1: r = -0.39, p< 0.05; sTNFR2:
r = -0.39, p<0.05). TNFα was only moderately correlated to sTNFR2 (r = 0.29, p< 0.01) and
not to sTNFR1 (r = 0.17, p = 0.059). No significant correlations were found between both
sTNFR and clinical variables listed in Table 1.
sTNFR1, sTNFR2 and outcome (death or first non-fatal CVE)
In univariate Cox proportional hazards analysis, sTNFR1 [Hazard ratio (HR): 1.49, 95% confi-
dence interval (CI): 1.28–1.75] and sTNFR2 [HR: 1.13, 95% CI: 1.06–1.20] were associated to
adverse outcomes. Older age, a higher CRP, a lower albumin concentration, a history of cardio-
vascular disease and diabetes mellitus also showed an association (Table 2). Kaplan Meier sur-
vival curves for both receptors are depicted in Fig. 2. For both sTNFRs, concentrations above
the median were associated with higher event rates.
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In multivariate models, sTNFR1 and to a smaller extent sTNFR2 remained significantly as-
sociated to outcome. In the first model (Table 3A) after adjustment for age and gender, both
sTNFRs had an increased HR of 1.52, 95% CI 1.30–1.77 (sTNFR1) and 1.07, 95% CI 1.03–1.21
(sTNFR2). When further adjustments were made for possible confounders which were
Table 1. Baseline characteristics of the entire study population and according to the occurrence or not of the studied events.
Variable Entire cohort Death or ﬁrst CVE
No Yes p-value
N = 131 N = 91 N = 40
Age (years) 73 [62–89] 70 [58–77] 78 [69–83] <0.001
Gender (M) 83 (63.4) 56 (61.5) 27 (67.5) 0.51
BMI (kg/m2) 28.3 ± 5.7 28.2 ± 5.0 28.4 ± 7.1 0.83
MAP (mmHg) 99 ± 13 100 ± 13 99 ± 14 0.84
PP (mmHg) 61 ± 19 60 ± 18 65 ± 20 0.10
HR (/min) 69 ± 13 69 ± 13 72 ± 14 0.29
eGFR (ml/min/1.73m2) 22.8 [16.1–27.0] 23.0 [16.6–27.5] 21.2[15.5–26.4] 0.40
CVD 64 (48.1) 38 (41.8) 26 (65.0) 0.02
DM 51 (38.9) 29 (31.9) 22 (55.0) 0.02
Malignancy 32 (24.4) 19 (20.9) 13 (32.5) 0.15
Cholesterol 90 (68.7) 60 (65.9) 30 (75.0) 0.30
AHT 108 (82.4) 75 (82.4) 33 (82.5) 0.99
Smoking (active) 12 (9.1) 9 (10.5) 3 (7.9) 0.66
Start RRT during FU 35 (26.7) 27 (29.7) 8 (20.0) 0.25
Albumin (g/dl) 4.0 ± 0.9 4.2 ± 0.8 3.7 ± 1.0 <0.01
CRP (mg/l) 3.0 [1.0–8.0] 2.0 [0.9–4.0] 8.0 [2.3–12.0] <0.001
TNFα (pg/ml) 4.6 [3.7–6.0] 4.6 [3.3–5.5] 4.9 [3.8–6.8] 0.13
sTNFR1 (ng/ml) 4.0 [3.1–5.1] 3.8 [2.8–4.8] 4.7 [3.9–6.0] <0.001
sTNFR2 (ng/ml) 7.4 [5.8–9.4] 6.9 [5.2–8.8] 7.9 [6.4–12.0] <0.001
Data are presented as means ± standard deviation or medians with interquartile range between square brackets. For binary variables, frequencies with
percentages between brackets are given. CVE: cardiovascular event, N = number of patients, M: male, BMI: body mass index, MAP: mean arterial
pressure, PP: pulse pressure, HR: heart rate, eGFR: estimated glomerular ﬁltration rate, CVD: history of cardiovascular disease, DM: diabetes mellitus,
cholesterol: hypercholesterolemia, AHT: arterial hypertension, RRT: renal replacement therapy, FU: follow-up, CRP: C-reactive protein, TNFα: tumor
necrosis factor alpha, sTNFR1: soluble tumor necrosis factor receptor 1, sTNFR2: soluble tumor necrosis factor receptor 2.
doi:10.1371/journal.pone.0122073.t001
Fig 1. Dot plots showing the association between sTNFR1 and sTNFR2 (panel A), eGFR and sTNFR1 (panel B) and sTNFR2 (panel C). sTNFR1:
soluble tumor necrosis factor receptor 1. sTNFR2: soluble tumor necrosis factor 2. eGFR: estimated glomerular filtration rate. R2: coefficient of determination.
The straight line represents the best fitted linear regression line with 95% confidence interval for the mean.
doi:10.1371/journal.pone.0122073.g001
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correlated to the sTNFRs in linear regression analysis (eGFR, CRP, TNFα), sTNFR1 and
sTNFR2 together with age remained independently associated to outcome (Table 3B). In the
third model after adjustment for age, CRP, a history of cardiovascular disease and diabetes mel-
litus, both receptors remained independently associated to outcome, the hazards ratio for
sTNFR1 (HR: 1.51, 95% CI: 1.30–1.77) again being higher than for sTNFR2 (HR: 1.13, 95% CI:
1.06–1.20). Age was the only significant covariate in the model with sTNFR1, while in the
model with sTNFR2, age and diabetes mellitus were significant covariables (Table 3C).
When including also albumin in this multivariate model, sTNFR1 (HR: 1.46, 95%CI: 1.16–
1.84) remained significantly associated to adverse outcome, while sTNFR2 was not. Albumin
itself was not a significant covariate.
In summary, after adjustment for significant clinical covariables, sTNFR1 and sTNFR2 re-
mained independently associated to increased risk of death or cardiovascular events. This asso-
ciation was stronger for sTNFR1 than for sTNFR2 (Table 3).
Subgroup analysis: patients without and with diabetes
Eighteen of the eighty patients without diabetes had an adverse event (22.5%). Patients, having
an event, were older (80 vs. 68.5 years, p< 0.001), had a higher CRP (9.0 vs. 2.0 mg/l,
p< 0.001), had more often a history of malignancy (50% vs. 19.4%, p< 0.01) and were less
likely to start RRT during FU (5.6% (n = 1) vs. 29% (n = 18), p< 0.05). There were no
Table 2. Univariate Cox proportional hazards analysis for outcome (death or first adverse cardiovas-
cular event).
Variable B HR [95% CI]
sTNFR1 (per ng/ml) 0.402 1.49 [1.28–1.75]***
sTNFR2 (per ng/ml) 0.118 1.13 [1.06–1.20]***
TNFα (per pg/ml) 0.024 1.02 [0.96–1.09]
CRP (per mg/l) 0.017 1.02 [1.01–1.03]***
Gender (M) 0.316 1.37 [0.71–2.68]
Age (per year) 0.058 1.06 [1.03–1.09]***
eGFR (per ml/min/1.73m2) -0.025 0.98 [0.93–1.03]
MAP (per mmHg) -0.001 1.00 [0.98–1.02]
PP (per mmHg) 0.014 1.01 [1.00–1.03]
Albumin (per g/dl) 0.036 0.71 [0.52–0.98]
BMI -0.001 1.00 [0.95–1.06]
CVD 0.757 2.13 [1.11–4.08]*
DM 0.774 2.17 [1.16–4.04]*
Malignancy 0.480 1.62 [0.83–3.14]
AHT -0.052 0.95 [0.42–2.15]
Cholesterol 0.304 1.36 [0.66–2.78]
Smoking -0.209 0.81 [0.25–2.64]
HR: Hazard ratio, CI: conﬁdence interval. In bold, variables with p-value < 0.05, included in the multivariate
model (Table 3, model 3).
*: p < 0.05.
***: p < 0.001.
sTNFR1: soluble tumor necrosis factor receptor 1, sTNFR2: soluble tumor necrosis factor receptor 2,
TNFα: tumor necrosis factor alpha, CRP: C-reactive protein, eGFR: estimated glomerular ﬁltration rate,
MAP: mean arterial pressure, PP: pulse pressure, BMI: body mass index, CVD: history of cardiovascular
disease, DM: diabetes mellitus, AHT: arterial hypertension, cholesterol: hypercholesterolemia.
doi:10.1371/journal.pone.0122073.t002
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differences for the other clinical variables listed in Table 1 (S1 Table). In univariate analysis
sTNFR1 and sTNFR2 were significantly associated to adverse outcome, as well as age, CRP and
malignancy (S2 Table). After adjustment for age, CRP and malignancy, only sTNFR1 remained
significant in the model with a HR of 1.85, 95% CI 1.38–2.47 (Table 4).
In the subgroup of diabetes patients (n = 51), only sTNFR1 and not sTNFR2 concentrations
were significantly higher in the patients reaching the composite endpoint (4.5 vs. 3.8 ng/ml,
p< 0.05) (S3 Table). In univariate analysis both receptors were associated to adverse outcome
(S4 Table). This significant association persisted only for sTNFR1 after adjustment for age,
gender, CRP and eGFR in multivariate analysis (HR: 1.35, 95% CI, 1.11–1.65).
Discussion
This study evaluated the value of sTNFR1 and sTNFR2 as biomarkers for their association to
the composite endpoint of all-cause mortality or first non-fatal cardiovascular event in a cohort
with advanced CKD irrespective of the underlying etiology. The main finding of this study is
that sTNFR1 and sTNFR2 are associated to adverse outcome, even after adjustment for clinical
covariables, such as age, gender, eGFR, CRP. The association with outcome was stronger for
sTNFR1 than for sTNFR2. In the subgroups of patients without and with diabetes only
sTNFR1 was after adjustment associated to outcome.
To the best of our knowledge, this is the first study to investigate associations between
sTNFR1 and sTNFR2 and adverse outcomes in advanced CKD irrespective of the etiology. The
study may be particularly relevant since by design, the narrow range of eGFR (<30 ml/min/
1.73m2) minimized the impact of eGFR on outcome, which was confirmed by the lack of asso-
ciation to adverse outcomes (Tables 2 and 3) and there is also no influence of dialysis therapy.
In spite of the small eGFR range, we found a relatively good correlation between eGFR and
sTNFR1 (r = -0.64) and sTNFR2 (r = -0.50), underscoring that sTNFR1 and sTNFR2 with re-
spective molecular weights of approximately 30 and 40 kDa, are probably mainly eliminated by
renal clearance [16–18].
Fig 2. Kaplan Meier survival plots for sTNFR1> or< than the median (4.0 ng/ml) and sTNFR2> or< than the median (7.4 ng/ml). sTNFR1: soluble
tumor necrosis factor receptor 1. sTNFR2: soluble tumor necrosis factor 2.
doi:10.1371/journal.pone.0122073.g002
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Also, in large cohort studies in the general population, sTNFR1 [19,20] and sTNFR2 [19,21]
have been associated to an increased risk for major cardiovascular events [19,21] or mortality
[20], even after adjustment for traditional risk factors [21]. However, in these cohorts, and in
contrast to our study (Table 3), no corrections were made for kidney function [21] or the asso-
ciation was only found when creatinine clearance ranged up to 75 ml/min, which implies a
much broader range of eGFR than in the present study [19]. As a consequence, it cannot be ex-
cluded that in these studies the sTNFR concentrations rather reflected the association of eGFR
with adverse outcomes than that of sTNFRs itself. In the present study, sTNFRs were more in-
formative for adverse outcome than what could be explained through their correlation with
eGFR alone, since associations of sTNFRs to adverse outcome remained significant after ad-
justment for eGFR, while eGFR was not significant (Table 3). This observation could strength-
en the hypothesis that sTNFRs are also markers for underlying pathophysiological
Table 3. Multivariate Cox proportional hazardsmodels for death or first CVE.
Variable B HR [95% CI] p-value
A. Model 1: sTNFR1 or sTNFR2, age, gender
A1. sTNFR1
sTNFR1 (per ng/ml) 0.417 1.52 [1.30–1.77] < 0.001
age (per year) 0.065 1.07 [1.03–1.11] < 0.001
gender (M) n.s.
A2. sTNFR2
sTNFR2 (per ng/ml) 0.135 1.14 [1.07–1.22] < 0.001
age (per year) 0.065 1.07 [1.03–1.10] < 0.001
gender (M) n.s.
B. Model 2: sTNFR1 or sTNFR2, age, gender, eGFR, CRP, TNFα
B1. sTNFR1
sTNFR1 (per ng/ml) 0.414 1.51 [1.30–1.77] <0.001
age (per year) 0.063 1.07 [1.03–1.10] <0.01
gender, CRP, eGFR n.s.
B2. sTNFR2
sTNFR2 (per pg/ml) 0.136 1.15 [1.08–1.22] <0.001
age 0.057 1.06 [1.02–1.10] <0.01
gender, CRP, eGFR, TNFα n.s.
C. Model 3: sTNFR1 or sTNFR2, age, CRP, CVD, DM
C1. sTNFR1
sTNFR1 (per ng/ml) 0.414 1.51 [1.30–1.77] <0.001
age (per year) 0.063 1.07 [1.03–1.10] <0.001
CRP, DM, CVD n.s.
C2. sTNFR2
sTNFR2 (per ng/ml) 0.119 1.13 [1.06–1.20] <0.001
age (per year) 0.063 1.07 [1.03–1.10] <0.001
DM 0.644 1.90 [1.02–3.56] <0.05
CRP, CVD n.s.
CVE: cardiovascular event, HR: Hazard ratio, CI: conﬁdence interval. In model 2: TNFα, only included in
model with sTNFR2. sTNFR1: soluble tumor necrosis factor receptor 1, sTNFR2: soluble tumor necrosis
factor receptor 2, TNFα: tumor necrosis factor alpha, eGFR: estimated glomerular ﬁltration rate, CRP: C-
reactive protein, TNFα: tumor necrosis factor alpha, CVD: history of cardiovascular disease, DM: diabetes
mellitus, n.s.: not signiﬁcant.
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mechanisms of cardiovascular risk in CKD. This is supported by findings in other populations
with increased cardiovascular risk. sTNFR1 at admission for acute myocardial infarction was
associated to infarct size and worse left ventricular function 4 months post-infarction [22], to
the composite endpoint of death and new onset heart failure [23] and to long term cardiac and
all-cause mortality post-infarction even when corrected for relevant covariates such as creati-
nine clearance [24].
This is also consistent with the increased mortality risk associated to sTNFR1 in patients
with diabetic nephropathy [12,13]. In the present study, the association between sTNFRs and
outcome was also confirmed in the subgroup of patients without diabetes (Table 4), be it more
strongly for sTNFR1 (in univariate and multivariate analysis) than for sTNFR2 (only in univar-
iate analysis). In diabetic patients, only sTNFR1 was associated to adverse outcome.
Remarkably, although linked to each other in the same inflammatory TNFα–pathway,
sTNFR1 and sTNFR2 do not entirely yield the same information, despite the strong mutual
correlation between both receptors as observed in our study (r = 0.76) and also reported previ-
ously [11]. sTNFR1 did not correlate to TNFα, while a significant but modest correlation was
found for sTNFR2 (r = 0.29). In the subgroups of patients without or with diabetes only
sTNFR1 and not sTNFR2 was associated to outcome in multivariate analysis. This could point
towards different mechanisms of generation and elimination of sTNFR1, sTNFR2 and TNFα,
independently of each other. The pathophysiological processes behind their presence in circu-
lation in CKD are incompletely understood and need further investigation in order to explain
these different associations with outcome.
Constitutively, both sTNFRs are released from cell membranes by shedding [18,25] or as
full-length receptors in exosomes [26,27]; the full-length sTNFR1 in exosomes being the most
abundant form of sTNFR1 in serum of healthy controls [27]. Both forms are capable of binding
TNFα [18,27]. Following acute pro-inflammatory stimuli, shedding is intensified, resulting in
an increase in circulating sTNFR concentration [25,28] and in a possible modulation of im-
mune response [29]. The function of these soluble receptors is debated: they are inhibitors for
TNFα, especially in acute inflammatory settings [18,30], but, in more chronic conditions and
in proportion to their concentration, they also increase the half-life of TNFα and may act as
slow-release reservoirs of TNFα, enhancing its cytotoxicity [31]. Which process prevails in
CKD still needs to be elucidated, although the sTNFR concentration range (3–12 ng/ml) for
Table 4. Multivariate Cox proportional hazardsmodel for death or first CVE in the subgroup of non di-
abetic patients.
Variable B HR [95% CI] p-value
Full model with sTNFR1
sTNFR1 (per ng/ml) 0.615 1.85 [1.38–2.47] <0.001
age (per year) 0.082 1.09 [1.03–1.15] <0.01
CRP, malignancy n.s.
Full model with sTNFR2
CRP (per mg/l) 0.039 1.04 [1.02–1.06] <0.001
age (per year) 0.065 1.07 [1.01–1.13] <0.05
sTNFR2 (per ng/ml), malignancy n.s.
CVE: cardiovascular event, HR: Hazard ratio, CI: conﬁdence interval, sTNFR1: soluble tumor necrosis
factor receptor 1, sTNFR2: soluble tumor necrosis factor receptor 2, TNFα: tumor necrosis factor alpha,
eGFR: estimated glomerular ﬁltration rate, CRP: C-reactive protein, TNFα: tumor necrosis factor alpha,
n.s.: not signiﬁcant.
doi:10.1371/journal.pone.0122073.t004
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which Aderka et al. [31] found a prolonged activity of TNFα function, corresponds to concen-
trations found in CKD. Together with our findings of a relationship with adverse outcome, this
could indicate that sTNFRs in CKD would rather increase the negative effects of TNFα than
act as TNFα-inhibitors.
The limitations of the study are: the results cannot be generalized to all CKD stages, since
we restricted the evaluation to CKD stage 4 and 5 intentionally to evaluate both receptors in a
narrow range of eGFR, which also resulted in a rather small population. Furthermore, based on
our results it is not yet possible to draw conclusions on the potential use or incremental value
of these markers in clinical situations. Nevertheless, the study unravelled convincing correla-
tions between sTNFRs and outcomes even after adjustment for confounders such as eGFR or
diabetes. Hence our data underscore the relationship of TNFRs, with hard clinical outcomes ir-
respective of underlying kidney disease and the presence or absence of diabetes. The fact that
especially sTNFR1 was consistently associated to different outcomes in advanced CKD as
shown in this study as well as in community-based and specific high risk populations such as
post-myocardial infarction, offers a strong argument in favour for its further evaluation in larg-
er CKD cohorts.
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